Reduced bone mineral density in men following chemotherapy for Hodgkin's disease.
We have measured bone mineral density (BMD) in 29 men, mean age 35.0 (range 19.7-58.0) years, with testicular damage following MVPP or hybrid chemotherapy for Hodgkin's disease. Forearm cortical bone mineral content (BMC) and lumbar spine and femoral neck integral BMD were measured 3.4 (1.1-6.8) years after completion of chemotherapy, and results expressed as Z (standard deviation) scores. There was a significant reduction in forearm cortical BMC (median BMC 1.727 g cm-1, median Z-score -0.8, P < 0.0005), in lumbar spine integral BMD (median BMD 1.141 g cm-2, median Z-score -0.6, P < 0.0005) and in femoral neck integral BMD (median BMD 0.991 g cm-2, median Z-score -0.4, P < 0.05). There was no significant correlation between Z-score and time elapsed since completion of chemotherapy, and no significant difference in Z-score according to type of chemotherapeutic regimen or number of cycles of chemotherapy received. In conclusion, men who are in complete remission following treatment of Hodgkin's disease have reduced cortical and trabecular BMD. Possible causes include mild hypogonadism secondary to chemotherapy-induced impairment of Leydig cell function, a direct effect of chemotherapy on bone, an effect of high-dose glucocorticoid on bone or an effect of Hodgkin's disease per se.
Holmes
S J
SJ
Department of Endocrinology, Christie Hospital NHS Trust, Manchester, UK.
Whitehouse
R W
RW
Clark
S T
ST
Crowther
D C
DC
Adams
J E
JE
Shalet
S M
SM
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects*; D005047:Etoposide / Q000009:adverse effects; D005640:Follicle Stimulating Hormone / Q000097:blood; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008466:Mechlorethamine / Q000009:adverse effects; D008875:Middle Aged; D011239:Prednisolone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D014747:Vinblastine / Q000009:adverse effects
D012738:Sex Hormone-Binding Globulin; D011344:Procarbazine; D013739:Testosterone; D008466:Mechlorethamine; D014747:Vinblastine; D005047:Etoposide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D011239:Prednisolone